MiMedx Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . MiMedx Group
MDXG Stock  USD 5.20  0.02  0.38%   
MiMedx's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MiMedx's valuation are provided below:
Gross Profit
322.6 M
Profit Margin
0.1038
Market Capitalization
773.1 M
Enterprise Value Revenue
1.6238
Revenue
393.4 M
There are over one hundred nineteen available fundamental ratios for MiMedx, which can be analyzed over time and compared to other ratios. Active traders should verify all of MiMedx last-minute fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The current Market Cap is estimated to decrease to about 466.7 M. Enterprise Value is estimated to decrease to about 449.7 M

MiMedx Total Revenue

228.3 Million

Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 1.8 M or Selling General Administrative of 130 M, as well as many indicators such as Price To Sales Ratio of 4.43, Dividend Yield of 0.0 or PTB Ratio of 8.0. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
  
Build AI portfolio with MiMedx Stock
Check out the analysis of MiMedx Correlation against competitors.

MiMedx Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets318.7 M303.5 M155.2 M
Slightly volatile
Short and Long Term Debt Total16.9 M28.6 M16.8 M
Slightly volatile
Other Current Liabilities23.1 M41.3 M27.1 M
Slightly volatile
Total Current Liabilities31.7 M52.4 M37 M
Slightly volatile
Total Stockholder Equity233.2 M222.1 M97.6 M
Slightly volatile
Accounts Payable7 M8.5 M7.2 M
Slightly volatile
Cash126.1 M120.1 M56.7 M
Slightly volatile
Non Current Assets Total87 M82.8 M46.6 M
Slightly volatile
Non Currrent Assets Other685.2 K1.3 M757.6 K
Slightly volatile
Cash And Short Term Investments126.1 M120.1 M57.2 M
Slightly volatile
Common Stock Total Equity96.6 K101.7 K102.6 K
Slightly volatile
Common Stock Shares Outstanding96.3 M171.4 M107.1 M
Slightly volatile
Liabilities And Stockholders Equity318.7 M303.5 M155.2 M
Slightly volatile
Non Current Liabilities Total15.8 M29 M18.5 M
Slightly volatile
Other Current Assets6.1 M9 M7.1 M
Slightly volatile
Other Stockholder Equity343.2 M326.9 M168.4 M
Slightly volatile
Total Liabilities47.4 M81.4 M55.4 M
Slightly volatile
Total Current Assets231.7 M220.7 M108.7 M
Slightly volatile
Intangible Assets9.7 M13.4 M10 M
Pretty Stable
Common Stock102.1 K169.1 K109.4 K
Slightly volatile
Property Plant And Equipment Net8.5 M13.3 M9.9 M
Slightly volatile
Good Will12.3 M22.4 M13.8 M
Slightly volatile
Property Plant And Equipment Gross39.7 M37.8 M15.6 M
Slightly volatile
Short Term Debt1.6 M2.7 M1.5 M
Slightly volatile
Net Receivables67.4 M64.2 M31.5 M
Slightly volatile
Inventory28.7 M27.4 M12.7 M
Slightly volatile
Other Liabilities2.6 M2.1 M3.1 M
Slightly volatile
Long Term Debt Total74.8 M71.2 M52.8 M
Slightly volatile
Capital Surpluse157.7 M190.5 M148.1 M
Slightly volatile
Property Plant Equipment10.9 M12.9 M9.7 M
Slightly volatile
Long Term Investments2.6 M2.9 M3.2 M
Slightly volatile
Short and Long Term Debt1.6 M1.1 M1.1 M
Slightly volatile
Non Current Liabilities Other4.8 M8.5 M6.5 M
Slightly volatile
Net Invested Capital255.9 M243.7 M104 M
Slightly volatile
Net Working Capital85.8 M168.2 M52.9 M
Slightly volatile
Capital Stock125.7 K132.3 K10.9 M
Pretty Stable
Warrants101.2 M106.4 M93.2 M
Slightly volatile

MiMedx Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.7 M6.9 M4.2 M
Slightly volatile
Selling General Administrative130 M258.9 M153.1 M
Slightly volatile
Other Operating Expenses176.1 M333.5 M206.9 M
Slightly volatile
Research Development9.3 M14.2 M10.1 M
Slightly volatile
Total Operating Expenses151.1 M264.4 M176 M
Slightly volatile
Total Revenue228.3 M401.2 M220.2 M
Slightly volatile
Cost Of Revenue72.5 M69.1 M33.9 M
Slightly volatile
Reconciled Depreciation4.6 M5.4 M5.7 M
Slightly volatile
Non Recurring45.3 K47.7 K340.7 K
Slightly volatile

MiMedx Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation3.7 M6.9 M4.2 M
Slightly volatile
Capital Expenditures3.5 M1.9 M3.7 M
Very volatile
End Period Cash Flow126.1 M120.1 M55.1 M
Slightly volatile
Begin Period Cash Flow99 M94.3 M46.2 M
Slightly volatile
Stock Based Compensation12.3 M19.5 M12.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.434.6611.1024
Slightly volatile
PTB Ratio8.08.42485
Slightly volatile
Days Sales Outstanding72.2867.1766.1811
Slightly volatile
Book Value Per Share1.241.180.7696
Slightly volatile
Average Payables2.9 M2.8 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.0530.05580.1579
Slightly volatile
Capex To Depreciation0.30.320.9247
Slightly volatile
PB Ratio8.08.42485
Slightly volatile
EV To Sales4.184.410.8584
Slightly volatile
Inventory Turnover4.242.93.8172
Slightly volatile
Days Of Inventory On Hand100130124
Very volatile
Payables Turnover7.667.34.566
Slightly volatile
Research And Ddevelopement To Revenue0.03860.04070.2708
Slightly volatile
Capex To Revenue0.00530.00550.0311
Slightly volatile
Cash Per Share0.340.640.4529
Slightly volatile
Days Payables Outstanding49.1851.7795.3512
Slightly volatile
Intangibles To Total Assets0.130.140.2237
Slightly volatile
Current Ratio4.614.844.4663
Slightly volatile
Receivables Turnover5.345.6279.9958
Very volatile
Graham Number2.052.632.6032
Slightly volatile
Shareholders Equity Per Share1.241.180.7696
Slightly volatile
Debt To Equity0.140.150.4852
Pretty Stable
Capex Per Share0.01250.01320.0418
Slightly volatile
Average Receivables11.2 M10.7 M10.5 M
Slightly volatile
Revenue Per Share1.462.141.8283
Slightly volatile
Interest Debt Per Share0.140.160.1998
Slightly volatile
Debt To Assets0.10.110.1624
Very volatile
Operating Cycle210234194
Very volatile
Price Book Value Ratio8.08.42485
Slightly volatile
Days Of Payables Outstanding49.1851.7795.3512
Slightly volatile
Ebt Per Ebit1.351.121.2812
Pretty Stable
Company Equity Multiplier1.51.232.0387
Pretty Stable
Long Term Debt To Capitalization0.09230.09720.4244
Slightly volatile
Total Debt To Capitalization0.110.10.2102
Very volatile
Debt Equity Ratio0.140.150.4852
Pretty Stable
Quick Ratio4.364.244.164
Slightly volatile
Net Income Per E B T0.810.852.7825
Very volatile
Cash Ratio2.632.29012.2504
Slightly volatile
Days Of Inventory Outstanding100130124
Very volatile
Days Of Sales Outstanding72.2867.1766.1811
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.861.121.7405
Pretty Stable
Price To Book Ratio8.08.42485
Slightly volatile
Fixed Asset Turnover15.7127.1919.8542
Slightly volatile
Debt Ratio0.10.110.1624
Very volatile
Price Sales Ratio4.434.6611.1024
Slightly volatile
Asset Turnover1.051.191.2904
Slightly volatile
Price Fair Value8.08.42485
Slightly volatile

MiMedx Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap466.7 M919.5 M717.2 M
Slightly volatile
Enterprise Value449.7 M889 M691.7 M
Slightly volatile

MiMedx Fundamental Market Drivers

Forward Price Earnings19.5313
Cash And Short Term Investments104.4 M

MiMedx Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About MiMedx Financial Statements

MiMedx stakeholders use historical fundamental indicators, such as MiMedx's revenue or net income, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.4 M-1.5 M
Total Revenue401.2 M228.3 M
Cost Of Revenue69.1 M72.5 M
Stock Based Compensation To Revenue 0.06  0.05 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.01  0.01 
Revenue Per Share 2.14  1.46 
Ebit Per Revenue 0.15  0.16 

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
How To Invest In MiMedx
Details
Is MiMedx Stock a good investment?
Details
What is MiMedx's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of MiMedx Correlation against competitors.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Can Biotechnology industry sustain growth momentum? Does MiMedx have expansion opportunities? Factors like these will boost the valuation of MiMedx. Expected growth trajectory for MiMedx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating MiMedx demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth
1.138
Earnings Share
0.27
Revenue Per Share
2.668
Quarterly Revenue Growth
0.353
Return On Assets
0.1198
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that MiMedx's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MiMedx represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MiMedx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY